IMR Press / CEOG / Volume 45 / Issue 3 / DOI: 10.12891/ceog4076.2018

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Immune response to hepatitis B vaccine in children born to HBsAg positive mothers: a meta-regression analysis
Show Less
1 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, China
2 Department of Neurosurgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
Clin. Exp. Obstet. Gynecol. 2018, 45(3), 437–440; https://doi.org/10.12891/ceog4076.2018
Published: 10 June 2018
Abstract

Purpose: Mother-to-child transmission (MTCT) is the main mode of spread of hepatitis B virus (HBV), worldwide. The authors performed a meta-analysis to compare the effects of three measures for prevention of MTCT. Materials and Methods: Medline (PubMed) was searched and experts were contacted for references. Odds ratio (OD) and 95% confidence intervals (CI) were used as measures of effect sizes. Results: A meta-analysis was performed on randomized controlled trials and non-randomized studies comparing the index of MTCT among five groups of pregnant women. Among infants born to HBsAg-positive mothers, there were no significant differences in anti-HBs positive rates between the vaccine-only group and combined-immunization group by age 8-12 months. In infants aged 7- 15 months and infants aged 16–24 months, anti-HBs positive rate was 92.6% and 84.0% respectively. Immunoprophylaxis failure rate in mother's age < 28 group was significantly higher than that of ≥ 28 group, and that in vaccine-only group was significantly higher than vaccine plus HBIG group. Conclusions: HBIG and HB vaccine as an immune prophylaxis in infants born to HBV carrier mothers, beginning after birth, is effective in preventing MTCT of HBV.
Keywords
HBV
Mother-to-child transmission (MTCT)
Hepatitis B immunoglobulin (HBIG)
HB vaccine
Share
Back to top